NRX Pharma Licenses 70,000-Patient Data to Support FDA Fast Track for Suicide Treatment | NewsOut

Healthcare and biotech investors: NRX Pharmaceuticals, a clinical-stage biopharmaceutical company, has licensed real-world evidence from more than 70,000 U.S. patients treated with intravenous ketamine or nasal esketamine for depression and suicidal ideation.

Reporting from the New York Stock Exchange, Jane King explains that the data will support NRX’s Fast Track application for accelerated FDA approval of NRX-100 for suicidal ideation in depression and bipolar depression—a condition with no currently approved drug therapies, aside from electroconvulsive therapy.

#NRXPharma
#BiotechNews
#MentalHealthTreatment
#SuicidePrevention
#DepressionTreatment
#FDAFastTrack
#ClinicalData
#RealWorldEvidence
#KetamineTherapy
#HealthcareInnovation
#JaneKing
#NewsOut
#NYSE
#PharmaResearch